ArticleBritish journal of cancer2016
Pre-diagnostic circulating sex hormone levels and risk of prostate cancer by ERG tumour protein expression.
Article in British journal of cancer, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
14 citing papers in PubMed, 2 syntheses or guidelines pooled it, 23 citations in OpenAlex.
- Etiology of prostate cancer with the TMPRSS2:ERG fusion: A systematic review of risk factors.International journal of cancer · 2025Pooled it
- TMPRSS2:ERG Gene Fusions in Prostate Cancer of West African Men and a Meta-Analysis of Racial Differences.American journal of epidemiology · 2017Pooled it
- Interactions of obesity, body shape, diabetes and sex steroids with respect to prostate cancer risk in the UK Biobank cohort.Cancer medicine · 2024Article
- Transcriptomes of Prostate Cancer with TMPRSS2:ERG and Other ETS Fusions.Molecular cancer research : MCR · 2023Article
- Dual TMPRSS2:ERG Fusion in a Patient with Lung and Prostate Cancers.Diagnostics (Basel, Switzerland) · 2020Article
- The prognostic value of gender in gastric gastrointestinal stromal tumors: a propensity score matching analysis.Biology of sex differences · 2020Article
- Pre-diagnostic Serum Metabolomic Profiling of Prostate Cancer Survival.The journals of gerontology. Series A, Biological sciences and medical sciences · 2019Article
- Corpora amylacea in prostatectomy tissue and associations with molecular, histological, and lifestyle factors.The Prostate · 2018Article
- A Prospective Study of Aspirin Use and Prostate Cancer Risk byCancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology · 2018Article
- Inhibition of histamine receptor H3R suppresses prostate cancer growth, invasion and increases apoptosis via the AR pathway.Oncology letters · 2018Article
- Prostate Cancer Disparities by Race and Ethnicity: From Nucleotide to Neighborhood.Cold Spring Harbor perspectives in medicine · 2018Review
- Height, Obesity, and the Risk ofCancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology · 2018Article
- The Role of Immunohistochemical Analysis as a Tool for the Diagnosis, Prognostic Evaluation and Treatment of Prostate Cancer: A Systematic Review of the Literature.Frontiers in oncology · 2018Article
- Prostate Cancer Genetics: Variation by Race, Ethnicity, and Geography.Seminars in radiation oncology · 2017Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 3 institutions in 3 countries.
Funding
Abstract
backgroundExperimental studies have shown androgen receptor stimulation to facilitate formation of the TMPRSS2:ERG gene fusion in prostate cell lines. No study has tested whether higher pre-diagnostic circulating sex hormone levels in men increase risk of developing TMPRSS2:ERG-positive prostate cancer specifically.
methodsWe conducted a nested case-control study of 200 prostate cancer cases and 1057 controls from the Physicians' Health Study and Health Professionals Follow-up Study. We examined associations between pre-diagnostic circulating levels of total testosterone, free testosterone, DHT, androstanediol glucuronide, estradiol, and SHBG and risk of prostate cancer by TMPRSS2:ERG status. TMPRSS2:ERG was estimated by ERG immunohistochemistry. We used multivariable unconditional polytomous logistic regression to calculate odds ratios (ORs) and 95% confidence intervals (CIs) for risk of ERG-positive (n=94) and, separately, ERG-negative (n=106) disease.
resultsFree testosterone was significantly associated with the risk of ERG-positive prostate cancer (OR: 1.37, 95% CI: 1.05-1.77), but not ERG-negative prostate cancer (OR: 1.09, 95% CI: 0.86-1.38) (Pdiff=0.17). None of the remaining hormones evaluated showed clear differential associations with ERG-positive vs ERG-negative disease.
conclusionsThese findings provide some suggestive evidence that higher pre-diagnostic free testosterone levels are associated with an increased risk of developing TMPRSS2:ERG-positive prostate cancer.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.